Search Results 801-810 of 14002 for anti-TNF drugs

1. Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Non-Hodgkin Lymphoma or Histiocytic/Dendritic Cell Neoplasms - Mayo Clinic

   By condition, treatment or drug name ... The doses of both drugs received will depend on when the patient is enrolled on to the study. ... an anti-CD38 monoclonal ...

2. Mayo Clinic Minute: Weaning off popular weight-loss medications

   Many people have lost unwanted pounds by using popular injectable weight-loss medications such as Ozempic, Wegovy and Zepbound.

3. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC - Mayo Clinic

   Subjects who received prior systemic therapy (including chemotherapy, other anti ... TNFα blockers, anakinra, rituximab, abatacept, or tocilizumab);; Current ...

4. Myeloid Cell Interactions Modulate Combination Immunotherapy Outcomes in the Liver Tumor Microenvironment - Mayo Clinic Research

   We have conducted preliminary studies of combination anti-PD-1 and anti-PD-L1 ICI treatment on B16 tumors. Once inoculated, tumors rapidly grew logarithmically ...

5. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy. Participating Mayo Clinic locations. Study statuses change often. Please contact the study ...

6. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) - Mayo Clinic

   The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been ...

7. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) - Mayo Clinic

   The purpose of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of ...

8. Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma - Mayo Clinic

   Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...

9. Muscular dystrophy - Diagnosis & treatment - Mayo Clinic

   Read about different types of this progressive disease that interferes with the creation of new muscle, as well as treatments to help with symptoms.

10. Biomarker-guided CNI substitution in Kidney Transplantation Assessment - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy ... By condition, treatment or drug name ... anti-Tumor necrosis factor(TNF) Monoclonal antibodies (mAb), or ...